DelveInsight’s PD-L1 Inhibitors Market Analysis highlights a USD 36 billion market across the 7MM, led by Merck’s KEYTRUDA and BMS’s OPDIVO. Other key players include Genentech, AstraZeneca, Regeneron, and Pfizer. The emerging pipeline features sasanlimab, HLX43, and balstilimab. Patent expirations in 2028 are expected to reshape the competitive landscape with biosimilar entry...